Conduit Pharmaceuticals Inc (NASDAQ:CDT)’s traded shares stood at 7.56 million during the latest session, with the company’s beta value hitting 2.30. At the last check today, the stock’s price was $0.08, to imply a decrease of -11.41% or -$0.01 in intraday trading. The CDT share’s 52-week high remains $4.09, putting it -5012.5% down since that peak but still an impressive 37.5% since price per share fell to its 52-week low of $0.05. The company has a valuation of $9.03M, with an average of 184.62 million shares in intraday trading volume over the past 10 days and average of 51.38 million shares over the past 3 months.
Conduit Pharmaceuticals Inc (NASDAQ:CDT) trade information
After registering a -11.41% downside in the latest session, Conduit Pharmaceuticals Inc (CDT) has traded red over the past five days. The 5-day price performance for the stock is -8.17%, and -7.61% over 30 days. With these gigs, the year-to-date price performance is 9.77%. Short interest in Conduit Pharmaceuticals Inc (NASDAQ:CDT) saw shorts transact 3.57 million shares and set a 0.14 days time to cover.
CDT Dividends
Conduit Pharmaceuticals Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Conduit Pharmaceuticals Inc (NASDAQ:CDT)’s Major holders
Conduit Pharmaceuticals Inc insiders hold 49.12% of total outstanding shares, with institutional holders owning 4.06% of the shares at 7.97% float percentage. In total, 4.06% institutions holds shares in the company.
We also have Fidelity Small Cap Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Conduit Pharmaceuticals Inc (CDT) shares. Going by data provided on Oct 31, 2024, Fidelity Small Cap Index Fund holds roughly 233.35 shares. This is just over 0.19% of the total shares, with a market valuation of $17711.0. Data from the same date shows that the other fund manager holds a little less at 202.93, or 0.17% of the shares, all valued at about 15402.0.
